Key result
HCM Risk-SCD model accurately targets ICD therapy to patients at highest sudden cardiac death risk.
Why the study?
The accuracy of the HCM Risk-SCD model for targeting ICD therapy in patients with hypertrophic cardiomyopathy needed international external validation.
Does the HCM Risk-SCD model accurately predict sudden cardiac death risk to target implantable cardioverter defibrillator therapy in patients with hypertrophic cardiomyopathy?
Does the HCM Risk-SCD model accurately predict sudden cardiac death risk to target implantable cardioverter defibrillator therapy in patients with hypertrophic cardiomyopathy?
The 2014 ESC HCM Risk-SCD model is externally validated as an accurate prognostic tool for identifying hypertrophic cardiomyopathy patients who would benefit from ICD therapy.
Supports HCM Risk-SCD-guided ICD decisions in HCM; confirms accuracy in cohorts yet leaves open randomized outcome trials.
This study confirms that the HCM Risk-SCD model provides accurate prognostic information that can be used to target implantable cardioverter defibrillator therapy in patients at the highest risk of SCD.
No takes yet. Share an insight, caveat, or question.
O’Mahony et al. (2017) studied this question. The HCM Risk-SCD model provides accurate prognostic information to target implantable cardioverter defibrillator therapy in patients at the highest risk of sudden cardiac death.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: